Lancashire and South Cumbria
Formulary
Formulary
8 Malignant disease and immunosuppression
The majority of systemic anti-cancer therapies are not listed in this formulary as they are included in either the Lancashire and South Cumbria Cancer Alliance SACT protocols or the Cancer Drugs Fund list, produced by NHSE. |
08-02-04 Glatiramer acetate
| Glatiramer Acetate Copaxone® |
|
Formulary
|
pre-filled syringe 20mg/1ml, 40mg/1ml |
 NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
|
Links
- Drug Safety Udate April 2016: Natalizumab (Tysabri): progressive multifocal leukoencephalopathy - updated advice to support early detection
- LSC Breast Chemotherapy Protocols
- MHRA advice on risk of thromboembolism (Feb 2011)
- MHRA Drug Safety Update April 2016: Dimethyl fumarate (Tecfidera): updated advice on risk of progressive multifocal leukoencephalopathy
- MHRA Drug Safety Update Dec 2017: Fingolimod (Gilenya): new contraindications in relation to cardiac risk
- MHRA Drug Safety Update Dec 2017: Fingolimod (Gilenya): updated advice about risk of cancers and serious infections
- MHRA Drug Safety Update Jan 2021: Dimethyl fumarate (Tecfidera): updated advice on the risk of progressive multifocal leukoencephalopathy (PML) associated with mild lymphopenia
- MHRA Drug Safety Update Jan 2021: Fingolimod (Gilenya): updated advice about the risks of serious liver injury and herpes meningoencephalitis
- MHRA Drug Safety Update May 2016: Pomalidomide (Imnovid): risk of hepatitis B reactivation
- MHRA Drug Safety Update Oct 2020: Niraparib (Zejula): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment
- MHRA Drug Safety Update: Lenalidomide (Revlimid): update on risk of second primary malignancy
- MHRA Drug Sfety Update Sep 2019: Fingolimod (Gilenya): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception
- MHRA Dug Safety Udate April 2016: Fingolimod (Gilenya): risks of progressive multifocal leukoencephalopathy, basal-cell carcinoma, and opportunistic infections
- MHRA update on bradycardia and heart block
- MHRA: Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception
- MHRA: Fingolimod (Gilenya▼): new contraindications in relation to cardiac risk
- MHRA: Fingolimod (Gilenya▼): risks of progressive multifocal leukoencephalopathy, basal-cell carcinoma, and opportunistic infections
- MHRA: Fingolimod (Gilenya▼): updated advice about risk of cancers and serious infections
- MHRA: Fingolimod (Gilenya▼): updated advice about the risks of serious liver injury and herpes meningoencephalitis
- MHRA: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
- MHRA: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
- MHRA: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
- MHRA: Natalizumab (Tysabri▼): progressive multifocal leukoencephalopathy—updated advice to support early detection
- MHRA: Risk of thrombotic microangiopathy & nephrotic syndrome with interferon beta
MHRA: Safety update on risk of second primary malignancy- MHRA: Safety update on risk of thromboembolism
- NHS England national commissioning policy
- NHSE: National Cancer Drugs Fund list
- NHSE: Peginterferon alfa-2a and ropeginterferon alfa-2b to treat myeloproliferative neoplasms (all ages) [2420]
- NHSE: Peginterferon alfa-2a and ropeginterferon alfa-2b to treat myeloproliferative neoplasms (all ages) [2420]
- NICE New Medicine Evidence Summary 32: Relapsed and refractory multiple myeloma: pomalidomide
- NICE NG122 : Lung cancer: diagnosis and management
- NICE NG224: Melanoma: assessment and management
- NICE NG47: Haematological cancers: improving outcomes
- NICE NG52: Non-Hodgkin’s lymphoma: diagnosis and management
- NICE TA 200: Hepatitis C - peginterferon alfa & ribavirin
- NICE TA 303: Teriflunomide for relapsing remitting MS
- NICE TA 627: Lenalidomide with rituximab for previously treated follicular lymphoma
- NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
- NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
- NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
- NICE TA127: Multiple sclerosis - natalizumab
- NICE TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
- NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
- NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
- NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
- NICE TA200:Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
- NICE TA235: Osteosarcoma - mifamurtide: guidance
- NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
- NICE TA254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
- NICE TA281: Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal)
- NICE TA302: Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)
- NICE TA32: Beta interferon and glatiramer acetate for the treatment of multiple sclerosis
- NICE TA320: Dimethyl fumarate for multiple sclerosis
- NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
- NICE TA322: Lenalidomide for treating myelodysplastic syndromes
- NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
- NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
- NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
- NICE TA538: Dinutuximab beta for treating neuroblastoma
- NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
- NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
- NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
- NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
- NICE TA602: Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
- NICE TA603: Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)
- NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
- NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
- NICE TA656: Siponimod for treating secondary progressive multiple sclerosis
- NICE TA656: Siponimod for treating secondary progressive multiple sclerosis
- NICE TA662: Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)
- NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
- NICE TA680: Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
- NICE TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
- NICE TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
- NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
- NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
- NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
- NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
- NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
- NICE TA767: Ponesimod for treating relapsing–remitting multiple sclerosis
- NICE TA767: Ponesimod for treating relapsing–remitting multiple sclerosis
- NICE TA774: Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)
- NICE TA784: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
- NICE TA794 : Diroximel fumarate for treating relapsing–remitting multiple sclerosis
- NICE TA794: Diroximel fumarate for treating relapsing–remitting multiple sclerosis
- NICE TA798: Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation
- NICE TA802: Cemiplimab for treating advanced cutaneous squamous cell carcinoma
- NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
- NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
- NICE TA828:Ozanimod for treating moderately to severely active ulcerative colitis
- NICE TA848 Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)
- NICE TA901:Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)
UKMI report on differences between bcg products